Analyzing...
Loading company...
Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. The company is headquartered in Noida, Uttar Pradesh and currently employs 1,034 full-time employees. The firm's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹8,280 Cr revenue.
COGS 31.9%, employees 32.6%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 5.6%▼ | 10.3% |
| ROCE | 6.4%▼ | 13.7% |
| Net Margin | 4.8%▼ | 7.6% |
| EBITDA Margin | 15.2%▼ | 15.4% |
| Debt To Equity | 0.45x▲ | 0.15x |
| Rev Growth 3yr | 9.7%▼ | 10.0% |
Historical valuation data not available.
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8,280 Cr +14.4% | ₹7,235 Cr +979.3% | ₹670 Cr -89.3% | ₹6,282 Cr +3.7% | ₹6,059 Cr -0.6% | ₹6,099 Cr -33.4% | ₹9,154 Cr +0.5% | ₹9,111 Cr |
| Other Income | ₹66 Cr +16.2% | ₹57 Cr +726.8% | ₹7 Cr -82.1% | ₹38 Cr -53.4% | ₹82 Cr +366.4% | ₹18 Cr -62.8% | ₹47 Cr +32.7% | ₹36 Cr |
| Total Income | ₹8,346 Cr +14.5% | ₹7,291 Cr +976.7% | ₹677 Cr -89.3% | ₹6,320 Cr +2.9% | ₹6,141 Cr +0.4% | ₹6,116 Cr -33.5% | ₹9,202 Cr +0.6% | ₹9,147 Cr |
| COGS | ₹2,644 Cr +14.1% | ₹2,317 Cr +982.4% | ₹214 Cr -88.6% | ₹1,878 Cr +26.2% | ₹1,488 Cr -3.1% | ₹1,536 Cr -51.1% | ₹3,141 Cr -10.8% | ₹3,522 Cr |
| ₹7,672 Cr +15.0% | ₹6,670 Cr +933.1% | ₹646 Cr -89.7% | ₹6,248 Cr +13.6% | ₹5,501 Cr +5.1% | ₹5,235 Cr -34.2% | ₹7,957 Cr -0.1% | ₹7,963 Cr | |
| Profit Before Tax | ₹614 Cr -37.4% | ₹981 Cr | ₹15 Cr -5.7% | ₹16 Cr -97.6% | ₹640 Cr -25.5% | ₹860 Cr -29.0% | ₹1,211 Cr +33.9% | ₹904 Cr |
| Exceptional Items | (₹59 Cr) ↓ Decline | ₹360 Cr ↑ Recovery | (₹17 Cr) +70.3% | (₹57 Cr) | ₹0.00 Cr +100.0% | (₹21 Cr) +38.7% | (₹35 Cr) +87.6% | (₹280 Cr) |
| ₹217 Cr +50.1% | ₹144 Cr | ₹10 Cr -89.4% | ₹93 Cr -57.4% | ₹217 Cr -26.8% | ₹297 Cr -4.8% | ₹312 Cr -4.4% | ₹327 Cr | |
| Net Profit | ₹398 Cr -52.5% | ₹836 Cr | ₹7 Cr ↑ Recovery | (₹65 Cr) ↓ Decline | ₹413 Cr -50.6% | ₹836 Cr -7.0% | ₹898 Cr +55.7% | ₹577 Cr |
| Profit (Owners) | ₹399 Cr -52.5% | ₹839 Cr | ₹8 Cr ↑ Recovery | (₹61 Cr) ↓ Decline | ₹414 Cr -50.5% | ₹836 Cr -6.9% | ₹898 Cr +56.4% | ₹574 Cr |
| Minority Interest | (₹1 Cr) +67.7% | (₹3 Cr) -604.5% | (₹0.44 Cr) +88.7% | (₹4 Cr) -323.9% | (₹0.92 Cr) -253.8% | (₹0.26 Cr) | ₹0.00 Cr -100.0% | ₹3 Cr |
| Other Comprehensive Income | ₹546 Cr +542.1% | ₹85 Cr | ₹5 Cr -97.5% | ₹220 Cr -9.6% | ₹244 Cr +40.0% | ₹174 Cr +426.3% | ₹33 Cr ↑ Recovery | (₹14 Cr) |
| EPS | ₹25.02 | ₹52.70 | ₹0.48 | (₹3.83) | ₹25.99 | ₹52.48 | ₹56.39 | ₹36.07 |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
| Profit Or Loss Of Associates | (₹0.30 Cr) +40.0% | (₹0.50 Cr) ↓ Decline | ₹2 Cr -80.3% | ₹12 Cr ↑ Recovery | (₹10 Cr) ↓ Decline | ₹11 Cr | ₹0.00 Cr | ₹0.00 Cr |
Jubilant Pharmova Limited has informed the Exchange about General Updates - Intimation to shareholders about deduction of tax at source (TDS) on Final Dividend for FY 2025-26, if approved by the membe...
Jubilant Pharmova Limited has informed the Exchange about General Updates-Intimation regarding letter(s) dispatched to the shareholders whose email IDs are not registered, for AGM Notice, TDS Communic...
Jubilant Pharmova Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 26, 2026
Jubilant Pharmova Limited has informed the Exchange - Submission of Copies of Newspaper Advertisement relating to Notice to Shareholders - Transfer of equity shares/dividend to IEPF
Jubilant Pharmova Limited has informed the Exchange - Communication sent to Shareholders relating to notice of transfer Shares/Dividend to IEPF
Jubilant Pharmova Limited has informed the Exchange - Submission of Copies of Newspaper Publications - Annual General Meeting of Jubilant Pharmova Limited scheduled to be held on Wednesday, August 26,...
Jubilant Pharmova Limited has informed the Exchange about General Updates - Newspaper Advertisements - Dispatch of Postal Ballot
Jubilant Pharmova Limited has informed the Exchange regarding Notice of Postal Ballot
Jubilant Pharmova Limited has informed the Exchange about General Updates
Jubilant Pharmova Limited has informed the Exchange about General Updates
Jubilant Pharmova Limited has informed the Exchange about General Updates
Jubilant Pharmova Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Jubilant Pharmova Limited has informed the Exchange about General Updates
Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication
Jubilant Pharmova Limited has informed the Exchange regarding Appointment of Mr. Arjun Shanker Bhartia as Joint Managing Director of the company w.e.f. Jun 01, 2026.